Natera Inc. Common Stock vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $28.38 (market cap $950.14M). The key difference: Natera Inc. Common Stock is far larger — about 60× Roundhill Innov-100 0DTE Covered Call Strat ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Roundhill Innov-100 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Roundhill Innov-100 0DTE Covered Call Strat ETF for 59 Days on average.
| NTRA | QDTE | |
|---|---|---|
Market Cap | $57.03B | $950.14M |
Volume | 1,131,157 | 170,009 |
Sector | Health | Income / Options Overlay |
52-Week High | $425.64 | $36.60 |
52-Week Low | $179.42 | $26.85 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $56.18B | — |
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
QDTE (Roundhill Nasdaq-100 0DTE Covered Call Strategy ETF) trades at $29.29, down 0.14% with a bearish technical signal. The fund provides weekly distributions but faces criticism for yield sustainability and NAV erosion. Recent dividend payments have declined from $0.28 to $0.11, reflecting volatility compression. Technical indicators show mixed signals with neutral oscillators but bearish moving averages.
Outlook remains cautious due to structural concerns about return-of-capital distributions and underperformance in bull markets. The 24-31% yield appears unsustainable, with the fund sacrificing upside potential. Key risks include NAV decay, fee drag, and dependence on market volatility. Analyst sentiment has turned neutral to negative on the strategy's long-term viability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →